David Alan Dodd
DirectorMr. David Alan Dodd had been the Chief Executive Officer and President of Geovax Labs, Inc. since September 5, 2018 until November 5, 2026 and had been its Chairman since January 01, 2011 until November 5, 2026 and has been its Director since March 17, 2010. Mr. Dodd joined the GeoVax Labs, Inc. on March 17, 2010. His executive management experience in the pharmaceutical and biotechnology industries. From September 2017 to April 2018, he served as Chief Executive Officer and as a member of the Board of Directors of Medizone International, Inc. (“Medizone”), a developer and manufacturer of disinfectant systems. On April 20, 2018, Medizone announced that certain of its creditors had commenced an involuntary bankruptcy proceeding under Chapter 11 of the United States Bankruptcy Code against Medizone. The creditors included Medizone’s former Chairman and Chief Executive Officer and its former Director of Operations. From April 2013 to July 2017, Mr. Dodd served as President and Chief Executive Officer and as a member of the Board of Directors, of Aeterna Zentaris Inc., a drug development company. He was Chairman of the Board of Aeterna Zentaris, Inc. from May 2014 to May 2016 and Director until May 2018. From December 2007 to June 2009, Mr. Dodd was President, Chief Executive officer and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. From October 2006 to April 2009, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team and the sale of the company to Stem Cells, Inc. in April 2009. Before that, Mr. Dodd served as President, Chief Executive Officer and Director of Serologicals Corporation before it was sold to Millipore Corporation in July 2006. Prior to his employment by Serologicals Corporation, Mr. Dodd served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and Chairman of its subsidiary Unimed Pharmaceuticals, Inc. He is also the Chief Executive Officer of RiversEdge BioVentures, an investment and advisory firm focused on the life sciences and pharmaceuticals industries, which he founded in 2009. Mr. Dodd holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management Program.
Positions
- Company NameGeoVax Labs, Inc.Stock CodeGOVXPositionDirectorColleagues
- MJMark J. NewmanChief Scientific Officer
- TOTyler O’BrienInterim CEO & Chairman of the Board
- ASAnna SkowronChief Financial Officer
- TOThomas O’BrienVice President of Quality Systems & Compliance
- JWJeffrey WelchHead of Process Development & Manufacturing Operations
- RTRobert T. McNallyIndependent Director
- TLTeresa LambeInfectious Disease & Vaccine Scientific Advisory Board Member
- LTLance TurtleInfectious Disease & Vaccine Scientific Advisory Board Member
